Child obesity in pandemic could have lifelong effects, study says
Researchers say children who gained weight in the pandemic could develop diseases later in life.
Similar Posts
Captain Sir Tom Moore: What has happened to his legacy?
How much money did Captain Tom raise and why is his family under the spotlight?
JN.1 variant no more severe than other COVID-19 strains, CDC says
Join Fox News for access to this content Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the…
Gene therapy breakthrough restores hearing in some deaf children
Gene therapy has successfully restored hearing in some children born with inherited deafness, health officials say. A study in China and another at the Children’s Hospital of Philadelphia documented significant improvements in hearing in treated children. Cochlear implants are commonly used for children with hereditary deafness, but gene therapy offers a potential treatment. Gene therapy…
Covid inquiry: UK's public services were 'depleted' when Covid hit
The nation’s health was declining and the NHS was struggling by 2020, the Covid inquiry hears.
These 4 anti-obesity drug stocks could soar, Berenberg says
The anti-obesity drug market is expected to remain in focus this year after a bumper 2023 for weight loss drugmakers Novo Nordisk and Eli Lilly , according to Berenberg. The Germany-headquartered investment bank expects a combination of new clinical data, and the expiry of Novo ‘s patent for the active ingredient in first-generation GLP-1 drugs,…
Pharma had a year full of firsts
Soumyabrata Roy | Nurphoto | Getty Images Drugmakers are closing out a year when they achieved several historic firsts that will shape the pharmaceutical industry in 2024 and beyond. The weight loss drug market transformed into the pharmaceutical industry’s newest gold rush this year, as demand for costly but highly effective treatments from Novo Nordisk…